Gilead Sciences Says It Will Meet Global Remdesivir Demand by October, GILD Stock Price Is Rising
Gilead has confirmed its capacities to produce Remdesivir in such volumes that will meet global demand. GILD stock is up.
GILD Stock Up 0.2% in Pre-market, European Union Inks Deal with Gilead Sciences for Remdesivir Supply
As it was proven that Remdesivir could reduce the risk of death from COVID-19, the EU has entered in agreement with Gilead for 30,000 of its antiretroviral drug doses. GILD stock is up in the pre-market.
GILD Stock Up 2%, Gilead Says Remdesivir Coronavirus Treatment Reduces Risk of Death
Gilead Sciences (GILD) stock price has risen on the news that Remdesivir saves more lives than it was previously thought. These results were revealed in a preliminary study.
GILD Stock Lost 1% Yesterday, Gilead Starts Early-Stage Trial for Its Remdesivir Drug
Gilead Sciences (GILD) stock is slightly down despite the progress that the company made in testing of its remdesivir drug that can be used as the coronavirus treatment.
GILD Stock Down Less Than 1% as Gilead Sciences Announces Long-Awaited Price for Remdesivir
Gilead Sciences (GILD) stock is slightly down after the company set the Remdesivir price for developed countries at $390 per dose. Privately insured patients will be charged $520 per dose.
Gilead Sciences (GILD) Stock Rose 1.5% Yesterday on Remdesivir $7 Billion Sales Prognosis
By
Darya Rudz
According to SVB Leerink analyst Geoffrey Porges, remdesivir price is likely to be $5,000 per course in the US, $4,000 per course in Europe, and around $2,000 in other markets. Gilead Sciences (GILD) stock keeps rising.
GILD Stock Down 3.5% Yesterday, Up 0.5% Now, Gilead to Supply Remdesivir to 127 Countries
By
Darya Rudz
As Gilead Sciences has said, the 127 countries on the remdesivir distribution list vary from low- to high-income countries. All of them face barriers in getting healthcare access. Meanwhile, now GILD stock is up after falling 3.53% yesterday.
Gilead (GILD) Stock Rises 0.68% in Pre-Market as Japan Set to Approve Remdesivir Today
Gilead (GILD) stock price is rising slightly after the Japanese government indicated that it could grant approval to its remdesivir drug to be used in the fight with COVID-19.
GILD Stock Up 3% Now, Gilead’s Remdesivir to be Available to U.S. Hospitals This Week
By
Darya Rudz
Following the Gilead CEO’s statement about exporting remdesivir to the U.S. hospitals, Gilead Sciences (GILD) stock is up. In the pre-market today, Gilead shares are over 3% up, trading at above $82.
Gilead (GILD) Stock Price Up Nearly 1% Now, CEO Confirms Over 50K Remdesivir Courses Ready
50,000 units of Remdesivir are ready for shipment. The drug has passed initial trials and has been proven to be effective in the treatment of COVID-19. Gilead (GILD) stock price is increasing.
GILD Stock Rose 5.68%, Gilead Reports ‘Positive Data’ on Treating COVID-19 with Remdesivir
By
Darya Rudz
Following the positive news on the remdesivir trial, Gilead stock rebounded. Yesterday, GILD closed at $83.14 per share or 5.68% up. After hours, it added another 2.29% to trade at $85.04. The price is also rising today in the-premarket trading.
Coronavirus Stocks: Why Gilead Sciences, Moderna, Inovio Pharmaceuticals, Novavax Rose
By
Darya Rudz
While tech shares are suffering drops, coronavirus stocks are soaring, The pharma companies are actively working on the development of a new vaccine.